Navigation Links
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Date:12/14/2007


Worldwide Rights for All Potential Uses, Excluding U.S. and Japan

No Other Existing Therapeutic Treatment for Celiac Disease

BASINGSTOKE, England and PHILADELPHIA, December 14 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announces that it has acquired the worldwide rights, excluding the U.S. and Japan, to AT-1001 from Alba Therapeutics Corporation (Alba). AT-1001 is Alba's lead inhibitor of barrier dysfunction in various gastrointestinal disorders that is currently in Phase 2 development for the treatment of Celiac disease. Shire has acquired rights to all uses for AT-1001, which may also be studied for the treatment of Crohn's disease and other indications.

Matthew Emmens, Chief Executive Officer, commented: "The licensing of AT-1001 from Alba is a natural fit to our growing portfolio of gastrointestinal products. This product will be marketed to specialist physicians and we would expect to use our existing European sales force that is currently establishing relationships and expertise in the GI area through the marketing of MEZAVANT XL."

Financial terms of the license are geared to the successful development and commercialization of the product. Shire will pay Alba an upfront license fee of $25 million and further development and sales-based milestones totalling to a maximum of $300.5M should the product reach blockbuster status. Shire will also pay royalties on net sales of the product, with tiered, single or double digit royalty rates.

Alba and Shire will form a joint development committee to monitor R&D activities of AT-1001. Alba will fund all development until AT-1001 has completed Proof of Concept, which is expected to be in the first half of 2009, after which Shire and Alba will share equally development costs under a joint development plan.

About Celiac disease:

Celiac disease is a T-cell mediated auto-immune dis
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... November 24, 2014 2014 Deep ... Industry is a professional and in-depth research report ... Dihydrazide information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/22/2014)... and London (PRWEB) November 21, 2014 Two ... will explore what comes next for ALS research and how ... , After the Ice Bucket Challenge: Where Does the ... Date: Tuesday, 2 December 2014, Time: 1:30pm ET, ... , Join expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor ...
(Date:11/22/2014)... IL (PRWEB) November 21, 2014 On ... competitors at the 2014 Emerging Medical Technologies Summit in ... Innovator Awards. Widely regarded among Silicon Valley investors ... medical device innovation, the win also positions Briteseed ... MedTech Innovator competition in 2015 and compete with other ...
(Date:11/21/2014)... -- , Todd Martensen se ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo empresarial y ... marcha para comenzar de forma rápida la comercialización de su ... en Europa   , KLOX Technologies ... siguientes nombramientos: Todd Martensen ha sido ...
Breaking Biology Technology:Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5
... - Human neural stem cells, exposed in a lab dish ... rates, suggesting that the hormone may play a role in ... study published this week in the online editions of the ... new work, conducted by a team of scientists at the ...
... Lands End, Inc., , Wisconsin-based online clothing retailer, introduced Thursday ... effort to take the guesswork out of online shopping. , ... men and women find clothes that fit correctly by modeling ... more life-like model that closely resembles the customer. , ,Our ...
... and Chemicon International, Inc. announced today ... and apply Madison-based Promegas DNA-directed, RNA interference (ddRNAi) ... division of Serologicals Corporation, will have the right ... ddRNAi-based products and reagents for life science research. ...
Cached Biology Technology:DHEA Boosts Growth Rate of Human Neural Stem Cells 2DHEA Boosts Growth Rate of Human Neural Stem Cells 3
(Date:11/18/2014)... Nov. 17, 2014 The Parenteral Drug Association (PDA) ... agencies will speak and at least seven more will participate ... the Omni Shoreham Hotel in Washington D.C. ... to have significant support from the regulatory agencies in ... in our effort to help advance the use ...
(Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3
... 15, 2013  Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ... and patented systems to various medical and retail related ... corporate governance and transparency in the mushrooming legal marijuana industry and ... the status of past, present, and future projects. ...
... 15, 2013   Evolution Marketing Research , a leading supplier ... three new industry professionals. Ian Fureman ... as Associate Methodologist; and Shannon Sesa ... Fureman brings to Evolution more than 14 years of ...
... 14, 2013) Through a collaborative genome-wide study on ... are associated with heart rate. Since heart rate ... provide a better understanding of genetic regulation of heart ... for new drugs to treat cardiovascular disease. The ...
Cached Biology News:Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 2Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 3Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 4Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 5Evolution Marketing Research Grows its Practice with Addition of Three Key Industry Professionals 2Evolution Marketing Research Grows its Practice with Addition of Three Key Industry Professionals 3Mount Sinai study identifies new gene variations associated with heart rate 2